Omeros Corporation (OMER) vs Ultragenyx Pharmaceutical Inc. (RARE)
A side-by-side comparison of Omeros Corporation and Ultragenyx Pharmaceutical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
OMER
Omeros Corporation
$18.69HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
RARE
Ultragenyx Pharmaceutical Inc.
$14.57HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — OMER vs RARE
growth of $100 · dividends reinvested · last 10yOMER +87.7% (+6.5%/yr)RARE -79.6% (-14.7%/yr)OMER compounded faster over this window
Log scale — wide-divergence pair
OMER RARE
OMER vs RARE: by the numbers
- •RARE is the larger company ($1.43B vs $1.35B market cap).
- •OMER is profitable (324.88% net margin) while RARE runs a net loss (-81.79%).
- •RARE grew revenue faster over the past five years (14.81% vs 0.90% CAGR).
Metrics side by side
Valuation
| Metric | OMER | RARE |
|---|---|---|
| P/E ratio | 10.87 | N/A |
| Forward P/E | 20.62 | N/A |
| P/S ratio | 35.21 | 2.00 |
Profitability
| Metric | OMER | RARE |
|---|---|---|
| Gross margin | 0.00% | 83.12% |
| Operating margin | 0.00% | -73.77% |
| Net margin | 324.88% | -81.79% |
| ROIC | -32.06% | -53.48% |
Growth (annualized)
| Metric | OMER | RARE |
|---|---|---|
| Revenue CAGR (5Y) | 0.90% | 14.81% |
| Total return CAGR (5Y) | 21.70% | -30.14% |
Frequently asked
- Which has grown faster, OMER or RARE?
- Over the past five years, RARE grew revenue faster — OMER at a 0.90% CAGR versus RARE at 14.81%.
- Is OMER or RARE more profitable?
- OMER runs the higher net margin — OMER at 324.88% versus RARE at -81.79%.
- How have OMER and RARE total returns compared?
- Over the past 10 years, OMER delivered 6.50% and RARE delivered -14.91% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Omeros P/E ratioOmeros ROEUltragenyx Pharmaceutical ROEOmeros operating marginUltragenyx Pharmaceutical operating marginOmeros revenue growthUltragenyx Pharmaceutical revenue growthOmeros free cash flowUltragenyx Pharmaceutical free cash flow
Omeros & Ultragenyx Pharmaceutical appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.